Monograph

C10AB02 - Bezafibrate

Propably not porphyrinogenic

Rationale

Substrate of CYP 3A4. Two references stating non-porphyrinogenicity. Occasional clinical experience of non-porphyrinogenicity

Chemical description

Cholesterol lowering clofibrate derivative, dose 600 mg/d. 95 % absorbed from the gut. Metabolized by CYP 3A4 . No data pointing to CYP-induction. Thunell, patient report (n=1): tolerated. Andersson, patient report (n=3): tolerated. South African list: use with care French list: authorized

IPNet drug reports

Uneventful use reported in 9 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes C10A / C10AB or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames